These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 10683860)

  • 1. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons.
    Kowall NW; Hantraye P; Brouillet E; Beal MF; McKee AC; Ferrante RJ
    Neuroreport; 2000 Jan; 11(1):211-3. PubMed ID: 10683860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
    J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells.
    Yeo S; Sung B; Hong YM; van den Noort M; Bosch P; Lee SH; Song J; Park SK; Lim S
    Gene; 2018 Jun; 661():189-195. PubMed ID: 29604467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mouse MPTP model: gene expression changes in dopaminergic neurons.
    Kühn K; Wellen J; Link N; Maskri L; Lübbert H; Stichel CC
    Eur J Neurosci; 2003 Jan; 17(1):1-12. PubMed ID: 12534964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
    Mandel S; Maor G; Youdim MB
    J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
    Rekha KR; Selvakumar GP; Santha K; Inmozhi Sivakamasundari R
    Biochem Biophys Res Commun; 2013 Nov; 440(4):664-70. PubMed ID: 24103762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
    Shimoji M; Zhang L; Mandir AS; Dawson VL; Dawson TM
    Brain Res Mol Brain Res; 2005 Mar; 134(1):103-8. PubMed ID: 15790534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein.
    Liu L; Arun A; Ellis L; Peritore C; Donmez G
    J Biol Chem; 2012 Sep; 287(39):32307-11. PubMed ID: 22898818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.
    Song DD; Shults CW; Sisk A; Rockenstein E; Masliah E
    Exp Neurol; 2004 Apr; 186(2):158-72. PubMed ID: 15026254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
    Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
    PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration.
    Gómez-Tortosa E; Gonzalo I; Newell K; García Yébenes J; Vonsattel P; Hyman BT
    Acta Neuropathol; 2002 May; 103(5):495-500. PubMed ID: 11935266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease.
    Lv Z; Jiang H; Xu H; Song N; Xie J
    J Neural Transm (Vienna); 2011 Mar; 118(3):361-9. PubMed ID: 20556443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
    Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
    J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The mechanism of Lewy body formation in Parkinson's disease].
    Wakabayashi K; Takahashi H
    Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson's Disease.
    Duperrier S; Bortolozzi A; Sgambato V
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
    Schlüter OM; Fornai F; Alessandrí MG; Takamori S; Geppert M; Jahn R; Südhof TC
    Neuroscience; 2003; 118(4):985-1002. PubMed ID: 12732244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
    Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
    Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
    J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.